Compare · NVO vs YMAB
NVO vs YMAB
Side-by-side comparison of Novo Nordisk A/S (NVO) and Y-mAbs Therapeutics Inc. (YMAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and YMAB operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $180.22B.
- NVO has hit the wire 9 times in the past 4 weeks while YMAB has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 20 for YMAB).
- Company
- Novo Nordisk A/S
- Y-mAbs Therapeutics Inc.
- Price
- -
- -
- Market cap
- $180.22B
- -
- 1M return
- +5.96%
- -
- 1Y return
- -14.37%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2018
- News (4w)
- 9
- 0
- Recent ratings
- 25
- 20
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
Latest NVO
- Novo launches the new Novocare®: Free support program connects people with Wegovy® in addition to home delivery, everyday support, wellness partners and rewards
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo and DJ Khaled team up to take fans behind the scenes of the iconic musician's real-life "Walk, Golf, and Wegovy®" diet and weight-loss routine
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest YMAB
- SEC Form 15-12G filed by Y-mAbs Therapeutics Inc.
- Director Hamill Laura returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Wg Biotech Aps closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by SVP, Danyelza Bus. Unit Head Gentilcore Douglas J
- Director Gill David N returned $50,095 worth of shares to the company (30,905 units at $1.62), closing all direct ownership in the company (SEC Form 4)
- Director Tyagi Ashu returned 25,080 shares to the company, closing all direct ownership in the company (SEC Form 4)
- CHIEF BUSINESS OFFICER Gad Thomas returned 60,235 shares to the company, closing all direct ownership in the company (SEC Form 4)
- EVP, CFO and Treasurer Pfreundschuh Peter P. returned 77,800 shares to the company, closing all direct ownership in the company (SEC Form 4)
- PRESIDENT & CEO Rossi Michael J returned 129,101 shares to the company, closing all direct ownership in the company (SEC Form 4)
- SVP & CHIEF OPERATING OFFICER Wilms Joris returned 39,301 shares to the company, closing all direct ownership in the company (SEC Form 4)